Ha Tay Pharmaceutical JSC (HNX: DHT)
Vietnam
· Delayed Price · Currency is VND
86,500
+500 (0.58%)
At close: Jan 24, 2025
Ha Tay Pharmaceutical JSC Balance Sheet
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
Cash & Equivalents | 90,270 | 90,270 | 301,790 | 93,132 | 59,669 | 60,494 | Upgrade
|
Short-Term Investments | 90,000 | 90,000 | 80,000 | 53,000 | 350,000 | - | Upgrade
|
Cash & Short-Term Investments | 180,270 | 180,270 | 381,790 | 146,132 | 409,669 | 60,494 | Upgrade
|
Cash Growth | -52.78% | -52.78% | 161.26% | -64.33% | 577.20% | 10.51% | Upgrade
|
Accounts Receivable | 124,096 | 124,096 | 87,350 | 109,915 | 121,112 | 249,858 | Upgrade
|
Other Receivables | 9,516 | 9,516 | 10,525 | 8,964 | 32,917 | 21,800 | Upgrade
|
Receivables | 133,612 | 133,612 | 97,875 | 118,879 | 154,029 | 271,658 | Upgrade
|
Inventory | 527,935 | 527,935 | 378,908 | 460,629 | 339,706 | 373,510 | Upgrade
|
Other Current Assets | 83,045 | 83,045 | 150,099 | 285,297 | 103,882 | 27,728 | Upgrade
|
Total Current Assets | 924,861 | 924,861 | 1,008,673 | 1,010,937 | 1,007,287 | 733,390 | Upgrade
|
Property, Plant & Equipment | 976,101 | 976,101 | 791,736 | 442,074 | 212,752 | 166,103 | Upgrade
|
Long-Term Investments | 19,336 | 19,336 | 33,969 | 11,144 | 9,486 | 8,002 | Upgrade
|
Other Intangible Assets | 1,377 | 1,377 | 1,377 | 1,593 | 1,810 | 2,027 | Upgrade
|
Other Long-Term Assets | 4,631 | 4,631 | 2,510 | 3,754 | 6,256 | 10,525 | Upgrade
|
Total Assets | 1,926,305 | 1,926,305 | 1,838,264 | 1,469,502 | 1,237,591 | 920,046 | Upgrade
|
Accounts Payable | 235,207 | 235,207 | 146,324 | 196,455 | 113,994 | 260,362 | Upgrade
|
Accrued Expenses | 20,104 | 20,104 | 11,573 | 16,251 | 14,674 | 12,668 | Upgrade
|
Short-Term Debt | 373,274 | 373,274 | 333,483 | 234,630 | 289,429 | 204,182 | Upgrade
|
Current Income Taxes Payable | 6,057 | 6,057 | 4,958 | 8,758 | 6,288 | 4,598 | Upgrade
|
Current Unearned Revenue | 909.3 | 909.3 | 1,008 | 785.26 | 551.02 | 553.13 | Upgrade
|
Other Current Liabilities | 132,201 | 132,201 | 98,643 | 106,263 | 54,143 | 83,097 | Upgrade
|
Total Current Liabilities | 767,752 | 767,752 | 595,988 | 563,143 | 479,079 | 565,460 | Upgrade
|
Long-Term Debt | 96,913 | 96,913 | 170,218 | 102,213 | - | - | Upgrade
|
Other Long-Term Liabilities | 4,880 | 4,880 | 4,908 | 5,306 | 5,167 | 4,973 | Upgrade
|
Total Liabilities | 869,545 | 869,545 | 771,114 | 670,662 | 484,245 | 570,433 | Upgrade
|
Common Stock | 823,418 | 823,418 | 823,418 | 264,088 | 264,088 | 211,274 | Upgrade
|
Additional Paid-In Capital | 97,320 | 97,320 | 97,320 | 315,934 | 315,934 | 1,000 | Upgrade
|
Retained Earnings | 90,280 | 90,280 | 99,006 | 81,831 | 79,048 | 82,134 | Upgrade
|
Treasury Stock | -8,084 | -8,084 | -8,084 | -8,084 | -8,084 | -8,084 | Upgrade
|
Comprehensive Income & Other | 26,612 | 26,612 | 26,612 | 119,572 | 78,779 | 39,903 | Upgrade
|
Total Common Equity | 1,029,546 | 1,029,546 | 1,038,273 | 773,341 | 729,766 | 326,227 | Upgrade
|
Minority Interest | 27,214 | 27,214 | 28,877 | 25,499 | 23,580 | 23,386 | Upgrade
|
Shareholders' Equity | 1,056,760 | 1,056,760 | 1,067,150 | 798,841 | 753,345 | 349,613 | Upgrade
|
Total Liabilities & Equity | 1,926,305 | 1,926,305 | 1,838,264 | 1,469,502 | 1,237,591 | 920,046 | Upgrade
|
Total Debt | 470,187 | 470,187 | 503,700 | 336,844 | 289,429 | 204,182 | Upgrade
|
Net Cash (Debt) | -289,917 | -289,917 | -121,910 | -190,711 | 120,240 | -143,688 | Upgrade
|
Working Capital | 157,109 | 157,109 | 412,684 | 447,795 | 528,208 | 167,930 | Upgrade
|
Tangible Book Value | 1,028,170 | 1,028,170 | 1,036,896 | 771,748 | 727,956 | 324,201 | Upgrade
|
Construction In Progress | 790,110 | 790,110 | 638,852 | 301,451 | 64,931 | 63,328 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.